Glucose-dependent insulinotropic polypeptide (GIP) receptor enhances insulin release in response to food intake and may contribute to weight loss
Signs you're ready to move to the next dose: GI symptoms (nausea, vomiting, diarrhea) have resolved or are minimal for at least 7 consecutive days Appetite suppression remains noticeable but you sense a plateau effect developing at the current dose You have completed at least 4 full weeks at the current dose level You have no significant intercurrent illness that might confuse attribution of new symptoms Signs to wait: Ongoing nausea or vomiting, even if mild, at the end of the current dose phase A recent GI illness (unrelated to the medication) that makes it hard to attribute current symptoms A major life stressor or schedule disruption that might amplify side effects Fewer than 4 weeks at the current dose, regardless of how you feel When in doubt, an additional week at the current dose costs very little
It was a pleasurable experience, and I will continue to be a customer long into the future
Stanley TL, Levitsky LL, Grinspoon SK, Misra M
Specifically, GLP-1R engagement may alleviate endoplasmic reticulum (ER) stress, suppress microglial overactivation, and attenuate the release of pro-inflammatory cytokines and hippocampal neuronal apoptosis
Melanotan-II is related to, but different from, afamelanotide, an approved drug used to treat the skin condition erythropoietic protoporphyria
